Articles published by Biomea Fusion, Inc.
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
March 31, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Biomea Fusion Announces Leadership Transition
March 25, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA

From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA


Biomea Fusion to Become a Diabetes & Obesity Medicines Company
January 13, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
January 07, 2025
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA

From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA






From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA


From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA


Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
October 29, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA

Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
October 21, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA

From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA


Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
October 01, 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers
BMEA
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.